FDA fires off another manufacturing-related CRL, this one to Hyloris
The FDA has rejected Hyloris Pharmaceuticals’ antiviral valacyclovir, an oral suspension for infections caused by herpes simplex and varicella-zoster viruses becasue of manufacturing problems.
